EMA’s CHMP Recommends Zytiga Combo Therapy for Certain Early-stage Prostate Cancer Patients

EMA’s CHMP Recommends Zytiga Combo Therapy for Certain Early-stage Prostate Cancer Patients
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that the prostate cancer combo therapy Zytiga (abiraterone acetate) plus prednisone/prednisolone in combination with androgen deprivation therapy (ADT) be approved in the European Union for the treatment of early stage prostate cancer, Janssen announced. The recommendation is for newly diagnosed, high-risk, metastatic

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. Lawrence Glickman says:

    Wow the bad ideas just keep on coming! Early stage PC patients scared of invasive treatments will go for this in a minute but what will they have accomplished? They will kill off the hormone sensitive cells and have a low PSA for a year or two and then watch as their PSA rises as the remaining cells become hormone resistant and the long slide towards a painful death starts to eat away at their self confidence and then finally their life. They will have missed the ideal time to have a cure and be done with it with one of the many “focal” (Less Invasive) treatments now offered. Please ask your Doctor if he can guarantee you that while you wait metastases will not occur and demand to see the 5 and 10 year statistics for this treatment. Here is a quote from the NCI (National Cancer Institute)
    “Doctors cannot predict how long hormone therapy will be effective in suppressing the growth of any individual man’s prostate cancer. Therefore, men who take hormone therapy for more than a few months will be regularly tested to determine the level of PSA in their blood. An increase in PSA level may indicate that a man’s cancer has started growing again. A PSA level that continues to increase while hormone therapy is successfully keeping androgen levels extremely low is an indicator that a man’s prostate cancer has become resistant to the hormone therapy that is currently being used.”

  2. Charl Malan says:

    The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that the prostate cancer combo therapy Zytiga (abiraterone acetate) plus prednisone/prednisolone in combination with androgen deprivation therapy (ADT) be approved in the European Union for the treatment of early stage prostate cancer, Janssen announced.

    This is great news! How can prostate cancer patients find out about The European Commission´s decision when it is announced?

Leave a Comment

Your email address will not be published. Required fields are marked *